Chimeric Therapeutics Limited (CHMMF)

Chimeric Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	3.97	-	-	-	-
Other Revenue	8.72	7.46	4.51	2.62	-
Revenue	12.68	7.46	4.51	2.62	-
Revenue Growth (YoY)	70.09%	65.52%	72.16%	-	-
Cost of Revenue	0.85	-	-	-	-
Gross Profit	11.84	7.46	4.51	2.62	-
Selling, General & Admin	6.45	9	11.73	7.9	8.97
Research & Development	10.79	10.19	14.43	6.12	3.78
Operating Expenses	18.33	19.76	29.49	17.19	14.85
Operating Income	-6.49	-12.31	-24.98	-14.57	-14.85
Interest Expense	-0.21	-0.33	-0.77	-0.64	-0.01
Interest & Investment Income	0.05	0.12	0.03	0.01	0
Currency Exchange Gain (Loss)	-0.11	0.06	-0.09	-0.53	-0.26
Other Non Operating Income (Expenses)	-	0.9	-	-	0
EBT Excluding Unusual Items	-6.77	-11.56	-25.82	-15.73	-15.11
Gain (Loss) on Sale of Assets	-0	-0	-0	-0	-
Other Unusual Items	-3.55	-0.96	-	-	-
Pretax Income	-10.32	-12.52	-25.82	-15.73	-15.11
Income Tax Expense	0.11	0.01	0.09	0.16	-
Net Income	-10.43	-12.53	-25.92	-15.9	-15.11
Net Income to Common	-10.43	-12.53	-25.92	-15.9	-15.11
Shares Outstanding (Basic)	1,352	696	433	360	182
Shares Outstanding (Diluted)	1,352	696	433	360	182
Shares Change (YoY)	94.34%	60.57%	20.37%	97.88%	-
EPS (Basic)	-0.01	-0.02	-0.06	-0.04	-0.08
EPS (Diluted)	-0.01	-0.02	-0.06	-0.04	-0.08
Free Cash Flow	-7.28	-7.54	-16.31	-13.17	-8.85
Free Cash Flow Per Share	-0.01	-0.01	-0.04	-0.04	-0.05
Gross Margin	93.32%	100.00%	100.00%	100.00%	-
Operating Margin	-51.14%	-165.01%	-554.44%	-556.82%	-
Profit Margin	-82.23%	-168.01%	-575.20%	-607.48%	-
Free Cash Flow Margin	-57.36%	-101.07%	-361.89%	-503.04%	-
EBITDA	-5.46	-11.22	-24.02	-13.62	-14
EBITDA Margin	-43.01%	-150.50%	-	-	-
D&A For EBITDA	1.03	1.08	0.97	0.95	0.85
EBIT	-6.49	-12.31	-24.98	-14.57	-14.85
EBIT Margin	-51.14%	-165.01%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.